论文部分内容阅读
目的:探究血府逐瘀汤联合亮丙瑞林治疗生育期子宫内膜异位症不孕临床疗效及安全性。方法:研究对象为68例生育期子宫内膜异位症所致不孕妇女,随机分成两组,每组34例。对照组予注射用醋酸亮丙瑞林微球。观察组在此基础上再予血府逐瘀汤治疗,均连续治疗24周。检测治疗前后性激素水平、子宫体积及Kupperman、VAS评分,记录并比较临床疗效、安全性及妊娠率。结果:与治疗前比较,两组FSH、LH及E2水平均显著性降低(P<0.01),子宫体积、Kupperman评分及疼痛VAS评分均显著降低(P<0.01);与对照组比较,观察组FSH、LH及E2水平均较低(P<0.01),子宫体积、Kupperman评分及疼痛VAS评分均较低(P<0.01),治疗有效率较高(P<0.05),随访妊娠率较高(P<0.05),不良反应的发生无差异(P>0.05)。结论:血府逐瘀汤联合亮丙瑞林对生育期子宫内膜异位症不孕妇女有较理想的临床疗效,可有效调节性激素水平,明显改善绝经及疼痛症状,提高远期妊娠率。
Objective: To investigate the clinical efficacy and safety of Xuefu Zhuyu Decoction combined with leuprolide in the treatment of infertility with endometriosis during pregnancy. Methods: A total of 68 infertile women with endometriosis during their reproductive years were randomly divided into two groups (n = 34 in each group). The control group was injected with leuprolide acetate microspheres. On the basis of this observation group, Xuefuzhuyu decoction was given again, all of which were continuously treated for 24 weeks. The levels of sex hormone, uterine volume and Kupperman, VAS score were measured before and after treatment. Clinical efficacy, safety and pregnancy rate were recorded and compared. Results: The levels of FSH, LH and E2 decreased significantly in both groups (P <0.01), and the volume of uterus, Kupperman score and pain VAS score decreased significantly compared with those before treatment (P <0.01). Compared with the control group, FSH, LH and E2 levels were lower (P <0.01), uterine volume, Kupperman score and pain VAS score were lower (P <0.01), treatment efficiency was higher P <0.05), no difference in adverse reactions (P> 0.05). Conclusion: Xuefu Zhuyu Decoction combined with leuprorelin has an ideal clinical effect on infertile women with endometriosis during pregnancy, which can effectively regulate sex hormone levels, significantly improve the symptoms of menopause and pain, and improve the long-term pregnancy rate.